Navigation Links
Questcor Pharmaceuticals to Present at the Jefferies Global Healthcare Conference on September 28, 2011
Date:9/19/2011

sms in children under two years of age. With respect to nephrotic syndrome, the FDA has approved Acthar to "induce a diuresis or a remission of proteinuria in the nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosus."  Questcor is also exploring the use of Acthar to treat systemic lupus erythematosus, for which Acthar is approved as both a maintenance therapy and to treat exacerbations.  Questcor is also exploring the possibility of developing markets for other on-label indications and the possibility of pursuing FDA approval of additional indications not currently on the Acthar label where there is high unmet medical need.  For more information, please visit www.questcor.com.

Note: Except for the historical information contained herein, this press release contains forward-looking statements that have been made pursuant to the Private Securities Litigation Reform Act of 1995. These statements relate to future events or our future financial performance. These statements are only predictions. Actual events or results may differ materially. Factors that could cause or contribute to such differences include, but are not limited to, the following:

  • Our reliance on Acthar for substantially all of our net sales and profits;
  • Reductions in vials used per prescription resulting from changes in treatment regimens by physicians or patient compliance with physician recommendations;
  • Our ability to generate revenue from sales of Acthar to treat on-label indications associated with NS;
  • Regulatory changes or other policy actions by governmental authorities and other third parties in connection with U.S. health care reform or efforts to reduce federal and state government deficits;
  • Our ability to receive high reimbursement levels from third party payers;
  • An increase in the proportion of our Acthar unit s
    '/>"/>

SOURCE Questcor Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Questcor Reports Solid Fourth Quarter Results
2. Questcor to Discuss Results From FDA Panel Meeting
3. Trading Halted Today in Questcor Pharmaceuticals Common Stock
4. Questcor to Present at the Jefferies 2010 Global Life Sciences Conference
5. Questcor Receives Notification of PDUFA Date Extension to September 11, 2010
6. Mitchell J. Blutt, M.D. Appointed to Questcor Board of Directors
7. Questcor to Present at UBS Global Life Sciences Conference
8. Questcor and Child Neurology Foundation Support the 2nd Annual Infantile Spasms (IS) Awareness Week
9. Questcor Teams With Child Neurology Foundation (CNF) to Fund Infantile Spasms Scientific Research
10. Questcor to Present at the 21st Annual Oppenheimer Healthcare Conference
11. Questcor Reports Third Quarter 2010 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... WOODCLIFF LAKE, N.J. and SAN DIEGO ... Pharmaceuticals, Inc. (NASDAQ: ARNA ) announced today that ... Phase 3 trials of lorcaserin entitled, "Early Weight Loss While ... 52 Weight-Loss Outcomes," was recently published in the online issue ... The Obesity Society. The objective of these analyses was to ...
(Date:7/30/2014)... , July 30, 2014  Lightlake Therapeutics Inc. ... treatments based on its expertise in opioid antagonists, ... commitment from a prominent international research and development ... on promoting innovative research-based initiatives, including those addressing ... spray for the delivery of naloxone that could ...
(Date:7/30/2014)... Medical Equipment Solutions, Corp. are pleased to announce ... (US Army) contract valued at over $2 million over ... and technical support staffing. As an 8-A Certified Woman ... (SBA), Medical Equipment is proud to support American Service ... equipment. The SBA 8-A certification is a favored Federal ...
Breaking Medicine Technology:Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 2Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 3Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 4Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 5Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 6Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 7Lightlake Therapeutics Inc. Receives Funding Commitment From A Prominent International Research And Development Foundation 2Lightlake Therapeutics Inc. Receives Funding Commitment From A Prominent International Research And Development Foundation 3Medical Equipment Solutions Corp. Awarded $2 Million contract To Service DoD 2
(Date:7/30/2014)... 2014 According to the American Cancer Society, ... in the United States in 2014. (1) NTC ... the mortgage and financial industry, has long been a proponent ... and the company has further demonstrated its commitment by participating ... & Tarpon Springs event to increase awareness and fundraising efforts ...
(Date:7/30/2014)... 30, 2014 A formal complaint ... Office against the maker of the dialysis products ... Medical Care defrauded the state, its residents, physicians ... dialysates, before they were recalled in 2012. There ... these products pending in the U.S. District Court, ...
(Date:7/30/2014)... July 29, 2014 (HealthDay News) -- A simple blood ... spina bifida, new research finds. The test would ... in a pregnant women,s red blood cells. The findings from ... -- could help doctors predict the risk of serious birth ... to the proper development of a growing fetus. In ...
(Date:7/30/2014)... 30, 2014 (HealthDay News) -- ,Middle-aged adults with a ... likely as others to develop severe memory problems later ... British researchers said their findings could help doctors identify ... from help for problem drinking. "We already know ... of current alcohol consumption -- that understanding is based ...
(Date:7/30/2014)... Loffler Companies, the leading business technology and services ... new production printing machines from Konica Minolta and Canon ... better. , With blazing 100 page-per-minute output speed in ... press raises the bar in digital productivity, saves space ... costs with simple operation and powerful in-line finishing. The ...
Breaking Medicine News(10 mins):Health News:NTC Takes Action Against Cancer With 5th Consecutive Relay For Life of Palm Harbor & Tarpon Springs, Raises Over $12,000 for Cancer Research 2Health News:NTC Takes Action Against Cancer With 5th Consecutive Relay For Life of Palm Harbor & Tarpon Springs, Raises Over $12,000 for Cancer Research 3Health News:NTC Takes Action Against Cancer With 5th Consecutive Relay For Life of Palm Harbor & Tarpon Springs, Raises Over $12,000 for Cancer Research 4Health News:Louisiana Attorney General Files Complaint Against GranuFlo Manufacturer, Baron and Budd Reports 2Health News:Louisiana Attorney General Files Complaint Against GranuFlo Manufacturer, Baron and Budd Reports 3Health News:Blood Test Might Help Prevent Certain Birth Defects 2Health News:Adults Who've Abused Alcohol May Be at Risk for Memory Problems 2Health News:Loffler Companies Introduces New Konica Minolta bizhub PRESS C1085/C1100 and Canon imagePRESS C800/C700 Devices 2Health News:Loffler Companies Introduces New Konica Minolta bizhub PRESS C1085/C1100 and Canon imagePRESS C800/C700 Devices 3
... Research Collaborative for Health, both in Ann Arbor, have ... disparities in access to liver transplantation among racial and ... of Liver Transplantation , a journal published by ... Study of Liver Diseases (AASLD). Organ allocation in ...
... Aug. 19 (HealthDay News)-- There were no smiles on the faces ... waiting on line for help from the Oregon Employment Department were ... lecture from a middle-aged woman, who leaned in close and whispered ... a lot of unhappy, stressed people here." At rows of ...
... ARBOR, Mich. A team of University of Michigan scientists ... lifespan of roundworms. Scientists who study aging have long known ... the goal is to find less drastic ways to achieve ... promising early evidence that scientists may succeed at finding targets ...
... Reporter , WEDNESDAY, Aug. 18 (HealthDay News) -- Quitting ... many headache-prone teens ease their suffering, new research suggests. ... between those three lifestyle factors and recurrent headaches among ... number of headaches teens get and forestall headaches for ...
... more than 1,800 years reduced the gastrointestinal side effects ... of the cancer treatment, Yale University researchers report. ... herbs, called PHY906, and is based on a herbal ... nausea, vomiting and diarrhea. The study, published August 18 ...
... transplantation (HCT) cures many blood diseases, two-thirds of long-term ... the procedure, according to a recent study published ... the American Society of Hematology. Overall, these patients were ... a severe or life-threatening health condition, such as cardiovascular, ...
Cached Medicine News:Health News:Hispanics and Asians less likely to receive liver transplants 2Health News:Hispanics and Asians less likely to receive liver transplants 3Health News:Jobless and Stressed but Holding Out Hope 2Health News:Discovery may aid search for anti-aging drugs 2Health News:Discovery may aid search for anti-aging drugs 3Health News:Bad Habits Tied to Recurrent Headaches in Teens 2Health News:Bad Habits Tied to Recurrent Headaches in Teens 3Health News:Chronic health conditions common for stem cell transplant survivors 2Health News:Chronic health conditions common for stem cell transplant survivors 3
... benefits of fibre bronchoscopy: The HF-compatible V ... all other fibre bronchoscopes are measured., ... PENTAX, including the FB-19TV, FB-18V and FB-15V ... and the pediatric FB-8V, offer much better ...
... therapeutic fiberoptic bronchoscopes offers ... channel with a slim ... channel allows for improved ... of cytology brushes. The ...
... from the latest 60 series bronchoscopes., ... range, focussing on providing clinicians with ... Olympus has a impressive range of ... in the respiratory tract to meet ...
... High performance fiberoptic imaging from ... ,Olympus has improved its fiberscope range, ... specifications and enhanced image performance. Olympus ... instruments for diagnosis and therapy in ...
Medicine Products: